Sun Pharma Advanced Research Company Ltd Stock Price Today (NSE: SPARC)
Fundamental Score
Sun Pharma Advanced Research Company Ltd Share Price Live NSE/BSE & Institutional Fundamental Analysis
Sun Pharma Advanced Research Company Ltd share price today is ₹134.32, up +0.00% on NSE/BSE as of 17 February 2026. Sun Pharma Advanced Research Company Ltd (SPARC) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹4.36K (Cr). The 52-week high for SPARC share price is ₹N/A and the 52-week low is ₹N/A.
Sun Pharma Advanced Research Company Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Sun Pharma Advanced Research Company Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Sun Pharma Advanced Research Company Share Price: A Financial Overview
The pharmaceutical industry is currently experiencing a period of dynamic innovation, driven by advancements in personalized medicine and biopharmaceuticals. In this context, understanding the financial health of individual companies is critical. This analysis examines the current standing of the Sun Pharma Advanced Research Company share price, currently at ₹139.160004, focusing on key financial indicators and comparing it to its sector peers. The absence of a Price-to-Earnings (PE) ratio for Sun Pharma Advanced Research Company suggests a lack of profitability, requiring a deeper investigation into its financial performance.
One of the most concerning metrics is the company's Return on Capital Employed (ROCE) of -297.83%. A negative ROCE indicates that the company is not generating profit from its invested capital. This significantly weakens any potential economic moat, as it suggests an inability to efficiently utilize resources and generate returns competitive with its peers. For example, contrasting Sun Pharma Advanced Research Company Ltd with peers like
Mankind Pharma Ltd regarding management quality, specifically their ability to generate positive returns on invested capital, becomes crucial.The comparison with sector peers such as Mankind Pharma Ltd, Smruthi Organics Ltd, and Balaxi Pharmaceuticals Ltd is essential to contextualize Sun Pharma Advanced Research Company's performance. Analyzing these peers' profitability, growth rates, and debt levels provides a benchmark against which to assess Sun Pharma Advanced Research Company's relative strengths and weaknesses. The negative ROCE raises questions about the sustainability of Sun Pharma Advanced Research Company's business model and its ability to compete effectively in the long term.
It's important to note that this analysis is based on publicly available data and forms a small part of a broader 80-parameter fundamental audit. This comprehensive audit, verified by Sweta Mishra, seeks to provide a more in-depth understanding of the company's financial health. This analysis is observational and does not constitute financial advice.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Sun Pharma Advanced Research Company Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of SPARC across key market metrics for learning purposes.
Positive Indicators
3 factors identified
Robust Profit Growth (29.45%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Balanced Promoter Holding (65.67%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
10 factors identified
Suboptimal ROCE (-297.83%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Margin Pressure Concerns (-163.17%)
Observation: Operating margins are below industry standards.
Analysis: OPM <5% may indicate pricing pressures or cost management challenges.
Revenue Contraction (-38.88%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions.
Limited Growth History (-1.35% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.
Weak Earnings Growth (2.39% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Stagnant Profit Growth (-1.73% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity.
Weak Interest Coverage (-11.81x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Negative Free Cash Flow (₹-1297.54 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Limited Institutional Interest (FII+DII: 2.81%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Sun Pharma Advanced Research Company Ltd Financial Statements
Comprehensive financial data for Sun Pharma Advanced Research Company Ltd including income statement, balance sheet and cash flow
About SPARC (Sun Pharma Advanced Research Company Ltd)
Sun Pharma Advanced Research Company Ltd (SPARC) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Pharmaceuticals sector with a current market capitalisation of ₹4.36K (Cr). Investors tracking SPARC share price can monitor key metrics including P/E ratio, promoter holding of 65.67%, and quarterly earnings growth.
Company Details
Key Leadership
SPARC Share Price: Frequently Asked Questions
What is the current share price of Sun Pharma Advanced Research Company Ltd (SPARC)?
As of 17 Feb 2026, 10:22 am IST, Sun Pharma Advanced Research Company Ltd share price is ₹134.32. The SPARC stock has a market capitalisation of ₹4.36K (Cr) on NSE/BSE.
Is SPARC share price Overvalued or Undervalued?
SPARC share price is currently trading at a P/E ratio of 0.00x, compared to the industry average of 31.77x. Based on this relative valuation, the Sun Pharma Advanced Research Company Ltd stock appears to be Fairly Valued against its sector peers.
What is the 52-week high and low of SPARC share price?
The 52-week high of SPARC share price is ₹N/A and the 52-week low is ₹N/A.
What factors affect the Sun Pharma Advanced Research Company Ltd share price?
Key factors influencing SPARC share price include quarterly earnings growth (Sales Growth: -38.88%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Sun Pharma Advanced Research Company Ltd a good stock for long-term investment?
Sun Pharma Advanced Research Company Ltd shows a 5-year Profit Growth of -1.73% and an ROE of N/A%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of N/A before investing in SPARC shares.
How does Sun Pharma Advanced Research Company Ltd compare with its industry peers?
Sun Pharma Advanced Research Company Ltd competes with major peers in the Pharmaceuticals. Investors should compare SPARC share price P/E of 0.00x and ROE of N/A% against the industry averages to determine competitive standing.
What is the P/E ratio of SPARC and what does it mean?
SPARC share price has a P/E ratio of N/Ax compared to the industry average of 31.77x. Investors pay ₹N/A for every ₹1 of annual earnings.
How is SPARC performing according to Bull Run's analysis?
SPARC has a Bull Run fundamental score of 18.3/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does SPARC belong to?
SPARC operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Sun Pharma Advanced Research Company Ltd share price.
What is Return on Equity (ROE) and why is it important for SPARC?
SPARC has an ROE of N/A%, which suggests challenges in generating returns from shareholders equity. ROE measures how efficiently Sun Pharma Advanced Research Company Ltd generates profits from shareholders capital.
How is SPARC debt-to-equity ratio and what does it indicate?
SPARC has a debt-to-equity ratio of N/A, which indicates conservative financing with low financial risk.
What is SPARC dividend yield and is it a good dividend stock?
SPARC offers a dividend yield of 0.00%, meaning you receive ₹0.00 annual dividend for every ₹100 invested in Sun Pharma Advanced Research Company Ltd shares.
How has SPARC share price grown over the past 5 years?
SPARC has achieved 5-year growth rates of: Sales Growth -1.35%, Profit Growth -1.73%, and EPS Growth 2.39%.
What is the promoter holding in SPARC and why does it matter?
Promoters hold 65.67% of SPARC shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Sun Pharma Advanced Research Company Ltd.
What is SPARC market capitalisation category?
SPARC has a market capitalisation of ₹4358 crores, placing it in the Small-cap category.
How volatile is SPARC stock?
SPARC has a beta of N/A. A beta > 1 suggests the Sun Pharma Advanced Research Company Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is SPARC operating profit margin trend?
SPARC has a 5-year average Operating Profit Margin (OPM) of -163.17%, indicating the company's operational efficiency.
How is SPARC quarterly performance?
Recent quarterly performance shows Sun Pharma Advanced Research Company Ltd YoY Sales Growth of -38.88% and YoY Profit Growth of 29.45%.
What is the institutional holding pattern in SPARC?
SPARC has FII holding of 1.76% and DII holding of 1.05%. Significant institutional holding often suggests professional confidence in the Sun Pharma Advanced Research Company Ltd stock.